Holen Sie sich die Stockscreener-App
0.899
1.81%
0.016
Handel nachbörslich:
.89
-0.009
-1.00%
Schlusskurs vom Vortag:
$0.883
Offen:
$0.88
24-Stunden-Volumen:
198.42K
Relative Volume:
0.65
Marktkapitalisierung:
$67.74M
Einnahmen:
$9.53M
Nettoeinkommen (Verlust:
$-44.61M
KGV:
-0.9879
EPS:
-0.91
Netto-Cashflow:
$-38.32M
1W Leistung:
+28.43%
1M Leistung:
+28.30%
6M Leistung:
-25.70%
1J Leistung:
+16.74%
1-Tages-Spanne:
$0.8701
$0.92
1-Wochen-Bereich:
$0.7002
$1.03
52-Wochen-Spanne:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Vergleichen Sie CUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.899 | 52.74M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
What analysts say about Cue Biopharma Inc. stockBreakthrough wealth creation - jammulinksnews.com
Cue Biopharma Inc. Stock Analysis and ForecastExceptional return forecasts - jammulinksnews.com
What drives Cue Biopharma Inc. stock priceExceptional profit velocity - jammulinksnews.com
Is Cue Biopharma Inc. a good long term investmentStrong return on assets - Autocar Professional
Why Cue Biopharma Inc. stock is on top investor watchlistsLong Term Safe Yield Focus - beatles.ru
Cue Biopharma shares fall 4.67% premarket despite reporting new complete response in clinical trial. - AInvest
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - The Manila Times
Breakthrough: New Cancer Drug Shows 88% Survival Rate in Head and Neck Cancer Phase 1 Trial - Stock Titan
How Cue Biopharma Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser
How Olin Corporation stock performs during market volatilityCapital Protected Stock Selections - Newser
What makes Cue Biopharma Inc. stock price move sharplyBig Return Stock Tips - Newser
Why Cue Biopharma Inc. stock attracts strong analyst attentionSwing Trade Signals - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Shares - Newser
Why Starz Entertainment LLC stock attracts strong analyst attentionSmart Return Focused Trading - Newser
What makes Southside Bancshares Inc. stock price move sharplyFree Stock Market Forums - Newser
Why FTAI Infrastructure Inc. stock attracts strong analyst attentionStable Stocks With High Yield - beatles.ru
EQBK issues 1.73M shares, completes NBC merger & adds new director | XPON SEC FilingForm 8-K - Stock Titan
Funko (FNKO) CEO Cynthia Williams Resigns; Lunsford Named Interim | TBBK SEC FilingForm 8-K - Stock Titan
Head and Neck Cancer Pipeline Therapeutics Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Cue Biopharma shares fall 3.72% premarket after providing update on CUE-101 clinical trial. - AInvest
Cue Biopharma reports promising results for HPV+ head and neck cancer drug - Investing.com
Cue Biopharma Reports Promising Phase 1 Trial Results for CUE-101 in HPV+ Recurrent Metastatic Head and Neck Cancer - Nasdaq
Nasdaq Announces the Board of Directors of its U.S. Exchanges - The Manila Times
Breakthrough: New Cancer Drug Doubles Response Rate vs Standard Treatment in Head and Neck Cancer Trial - Stock Titan
Cue Biopharma Amends License Agreement with MIL 40G - TipRanks
KIDZW seeks OK for 2B share increase, $900M Solana funding plan | JXN SEC FilingForm 4 - Stock Titan
Cue Biopharma holds pre-IND meeting with FDA for lead autoimmune asset - BioWorld MedTech
CUE Receives FDA Pre-IND Feedback for CUE-401 Development | CUE Stock News - GuruFocus
Cue Biopharma's CUE-401: A Breakthrough in Autoimmune Therapies? - AInvest
Millennium Management LLC Reduces Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Bank of America Corp DE Acquires 85,113 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
CueBiopharma (CUE) Appoints Interim CFO as Kerri-Ann Millar Resi - GuruFocus
Cue Biopharma CFO Kerri-Ann Millar to Depart - marketscreener.com
Cue Biopharma CFO Resignation and Board Appointment - TipRanks
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO - marketscreener.com
Jane Street Group LLC Has $70,000 Stock Holdings in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):